The Pain Clinic Manual. 2nd ed

Sternberg, Timothy L.

doi:10.1097/00000539-200006000-00054

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Despite being the most widely used photosensitizer for oncologic PDT, it is known to have poor tissue selectivity and relatively low absorption of red light (ε≈2,500 M −1 cm −1 at 630 nm), 17 which is exacerbated by the poor tissue penetration of shorter wavelength visible light. These drawbacks spurred the development of higher-purity secondgeneration photosensitizers 18,19 aimed at increasing tumor selectivity to reduce the overall drug dose and thereby avoid the undesirable side effects associated with systemicallydelivered photosensitizers. Some second-generation photosensitizers (which include derivatives of porphyrins, chlorins, bacteriochlorins, phthalocyanines, pheophorbides, bacteriopheophorbides, and texaphyrins) were also designed to absorb longer wavelengths of light in an effort to improve tissue penetration for treating deep-seated and/or solid tumors.…”

Section: What Makes a Good Photosensitizer For Pdt?mentioning

confidence: 99%

Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433

et al. 2018

View full text Add to dashboard Cite

Transition metal complexes are of increasing interest as photosensitizers in photodynamic therapy (PDT) and, more recently, for photochemotherapy (PCT). In recent years, Ru (II) polypyridyl complexes have emerged as the most widely studied systems for both PDT and PCT. Their rich photochemical and photophysical properties derive from a variety of excited-state electronic configurations accessible with visible and near-infrared light, and these properties can be exploited for both energy-and electron-transfer processes that can yield highly potent oxygen-dependent and/or oxygen-independent photobiological activity. Selected examples highlight the use of rational design in coordination chemistry to control the lowest-energy triplet excited state configurations for eliciting a particular type of photoreactivity for PDT and/or PCT effects. These principles are also discussed in the context of the development of TLD1433, the first Ru(II)-based photosensitizer for PDT to enter a human clinical trial. The design of TLD1433 arose from a tumor-centered approach, as part of a complete PDT package that included the light component and the protocol for treating nonmuscle invasive bladder cancer. Briefly, this review summarizes *

show abstract

Section: What Makes a Good Photosensitizer For Pdt?mentioning

confidence: 99%